Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Gaceta médica de México
versión On-line ISSN 2696-1288versión impresa ISSN 0016-3813
Resumen
BARAJAS-GALINDO, David E.; VIDAL-CASARIEGO, Alfonso; GOMEZ-HOYOS, Emilia y GUERRA-GONZALEZ, María. Clinical experience with Tolvaptan outpatient use. Cost and effectiveness in 9 cases. Gac. Méd. Méx [online]. 2020, vol.156, n.1, pp.78-81. Epub 26-Mayo-2021. ISSN 2696-1288. https://doi.org/10.24875/gmm.19005250.
Introduction:
Tolvaptan introduction has constituted the main therapeutic novelty in the management of hyponatremia in recent years.
Objective:
To describe the experience with this drug at Complejo Asistencial Universitario de León, Spain.
Method:
Retrospective, observational study of tolvaptan outpatient use in a tertiary care hospital from March 2014 to August 2017.
Results:
A total of 9 patients were treated with tolvaptan in the outpatient setting. Eunatremia was reached in 24 h by 23.1%. After tolvaptan administration, a reduction in days of hospitalization was recorded (361 vs. 70; p = 0.007), especially in those days of hospitalization that were attributable to hyponatremia (306 vs. 49; p = 0.009).
Conclusions:
Long-term use of tolvaptan appears to be safe and is associated with a decrease in days of hospitalization.
Palabras llave : Tolvaptan; Hyponatremia; Sodium; Syndrome of inappropriate antidiuretic hormone secretion.